Influence of dosimetry method on bone lesion absorbed dose estimates in PSMA therapy: application to mCRPC patients receiving Lu-177-PSMA-I&T

BACKGROUND: Patients with metastatic, castration-resistant prostate cancer (mCRPC) present with an increased tumor burden in the skeleton. For these patients, Lutetium-177 (Lu-177) radioligand therapy targeting the prostate-specific membrane antigen (PSMA) has gained increasing interest with promisi...

Descripción completa

Detalles Bibliográficos
Autores principales: Brosch-Lenz, Julia, Uribe, Carlos, Gosewisch, Astrid, Kaiser, Lena, Todica, Andrei, Ilhan, Harun, Gildehaus, Franz Josef, Bartenstein, Peter, Rahmim, Arman, Celler, Anna, Ziegler, Sibylle, Böning, Guido
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952490/
https://www.ncbi.nlm.nih.gov/pubmed/33709253
http://dx.doi.org/10.1186/s40658-021-00369-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952490/
https://www.ncbi.nlm.nih.gov/pubmed/33709253
http://dx.doi.org/10.1186/s40658-021-00369-4

Ejemplares similares